Nasopharyngeal Cancer Clinical Trial
Official title:
An Open Label Study of First Line Chemotherapy With Xeloda in Combination With Cisplatin on Treatment Response in Patients With Metastatic Nasopharyngeal Cancer
This single arm study will assess the efficacy and safety of Xeloda + oxaliplatin when given as first line treatment for patients with metastatic nasopharyngeal cancer. Patients will receive Xeloda (1000mg/m2 bid orally from day 1 to day 14, followed by a rest period of 7 days) plus oxaliplatin (130mg/m2 iv infusion on day 1 of each 21 day cycle) for 6-8 cycles. The anticipated time on study treatment is until disease progression, and the target sample size is <100 individuals.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00370890 -
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
|
Phase 3 | |
| Recruiting |
NCT04340024 -
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
|
||
| Completed |
NCT00697619 -
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT00078546 -
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
|
Phase 1 | |
| Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT01074021 -
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03890185 -
Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC
|
Phase 2 | |
| Not yet recruiting |
NCT04158414 -
Applying PET/MR in Oncology - a Prospective Project
|
N/A | |
| Completed |
NCT02608073 -
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT03656250 -
Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
|
||
| Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
| Recruiting |
NCT04476641 -
A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors
|
Phase 2 | |
| Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06414577 -
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
|
Phase 2 | |
| Recruiting |
NCT03003182 -
A Study of Nasopharyngeal Carcinoma From Guangdong
|
N/A | |
| Not yet recruiting |
NCT06349889 -
Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT01094405 -
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT05305131 -
Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT01800071 -
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
|
Phase 1 | |
| Recruiting |
NCT00304694 -
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
|
N/A |